Search

Your search keyword '"Joly, Pascal"' showing total 1,108 results

Search Constraints

Start Over You searched for: Author "Joly, Pascal" Remove constraint Author: "Joly, Pascal"
1,108 results on '"Joly, Pascal"'

Search Results

3. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

4. S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV)

12. Polynomial Approximation

15. Fourier Approximation

22. Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database

24. Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study

25. Pemphigus Vulgaris

26. Diagnosis and management of pemphigus: Recommendations of an international panel of experts

27. Characterization of the skin microbiota in bullous pemphigoid patients and controls reveals novel microbial indicators of disease

28. How Do Experts Treat Patients with Bullous Pemphigoid around the World? An International Survey

29. The emergence of circulating activated autoreactive desmoglein 3-specific follicular regulatory T cells is associated with long-term efficacy of rituximab in patients with pemphigus vulgaris.

32. Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis: A multicenter, double-blind, randomized controlled study

33. S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology

34. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

35. Overview of Clinical Trials With Efgartigimod in Autoimmune Blistering Diseases: Pemphigus Vulgaris and Pemphigus Foliaceus (ADDRESS and ADDRESS+) and Bullous Pemphigoid (BALLAD and BALLAD+)

38. Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population

39. Large International Validation of ABSIS and PDAI Pemphigus Severity Scores

41. Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies

43. A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type

44. Corrigendum: S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV)

45. Efficacy and safety of anti-COVID-19 vaccination in patients with autoimmune blistering diseases: A French national study

47. SARS-CoV-2 Transmission from Presymptomatic Meeting Attendee, Germany

48. Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing

49. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

50. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study

Catalog

Books, media, physical & digital resources